Statin Selection and Intensity for Dyslipidemia Management

Introduction to Statin Therapy

The American College of Cardiology recommends initiating atorvastatin or rosuvastatin for newly diagnosed dyslipidemia, with the dose determined by the patient's cardiovascular risk category and required LDL-C reduction 1, 2

Patients with very high risk, including those with LDL-C ≥190 mg/dL, established ASCVD, diabetes with target organ damage or multiple risk factors, or chronic kidney disease stages 3-5, require high-intensity statin therapy 1, 2, 3, 4
High-risk patients, including those with 10-year ASCVD risk ≥10% or diabetes without target organ damage, age >40 years, require moderate- to high-intensity statin therapy 1, 2, 5, 6

High-intensity statin options include atorvastatin 40-80 mg daily and rosuvastatin 20-40 mg daily, which achieve ≥50% LDL-C reduction and demonstrate cardiovascular event reduction 1, 2, 7
Moderate-intensity statin options include atorvastatin 10-20 mg daily, rosuvastatin 5-10 mg daily, simvastatin 20-40 mg daily, and pravastatin 40-80 mg daily 1, 2, 5, 7

For patients with diabetes mellitus (age 40-75 years), start atorvastatin 10-20 mg or rosuvastatin 10 mg for LDL-C 70-189 mg/dL, and escalate to high-intensity statin if target organ damage or multiple risk factors are present 1, 2, 6
For patients with chronic kidney disease (eGFR <60 mL/min/1.73 m²), start atorvastatin 20 mg or rosuvastatin 10 mg with dose adjustment for renal function 4
For kidney transplant recipients, consider highest risk and treat with statins as initial therapy for elevated LDL-C, starting with atorvastatin or rosuvastatin at moderate intensity 8

Do not start simvastatin 80 mg due to increased myopathy and rhabdomyolysis risk, and do not rely solely on LDL-C levels to determine statin eligibility 1, 2, 6, 7
Do not use low-intensity statins for high-risk patients, as they require at least moderate-intensity therapy to achieve meaningful cardiovascular risk reduction 1, 2, 3